Most current discussion about AI-assisted clinical trial discovery assumes that a person is actively asking the questions.
The next development may be different.
AI agents are being designed not merely to respond to individual prompts, but to carry out multi-step tasks on a user’s behalf. An agent might search several sources, compare options, identify inconsistencies and return a filtered shortlist before the user examines any individual study.
That changes the visibility challenge.
A human patient may tolerate ambiguity, follow links or ask a site to clarify something that is unclear. An AI agent may evaluate dozens of possible studies quickly and deprioritise those for which eligibility, purpose, burden, location or contact pathways cannot be confidently established.
The question therefore moves from:
Can a patient find the trial?
to:
Will an AI agent decide that the trial is sufficiently relevant and credible to show to the patient at all?
The same principle could apply beyond patient discovery. Sponsors and CROs may increasingly use agentic systems to research sites, investigators and vendors. Sites may use them to examine competing studies, sponsor expectations and protocol requirements.
In each case, public information becomes part of an automated filtering process.
This does not mean organisations should fill their websites with machine-oriented language at the expense of human communication. Patients still need empathy, clarity and appropriate reassurance. But important claims also need to be explicit, structured and supported.
An AI agent should be able to establish such things as:
- what the trial or organisation actually offers
- which population or therapeutic area is relevant
- what evidence supports claims of experience or capability
- whether information is consistent across sources
- what practical burden or operational requirement is involved
- how the option compares with credible alternatives
- what action can be taken next
Information that is vague or fragmented may not simply produce a weaker impression. In an agent-mediated process, it may become a reason for exclusion before meaningful human consideration begins.
This creates what I describe as an interrogable information standard. Public information must be capable of being questioned, cross-referenced and compared by systems that prioritise explicit evidence over implied meaning.
Clinical Trials AI Visibility is therefore not only about what ChatGPT or Gemini says during one test. It is about whether a study, site, CRO or service has created a public information environment robust enough for increasingly automated research and evaluation.
The organisations that address that standard early will be better positioned as AI moves from answering questions to helping make preliminary choices.
Read the full Clinical Leader article – originally published on 13 May 2026.